# Safety and Clinical Activity of Itolizumab in aGVHD

> **NCT05823675** · PHASE1 · UNKNOWN · sponsor: **Biotech Pharmaceutical Co., Ltd.** · enrollment: 44 (estimated)

## Conditions studied

- Acute Graft Versus Host Disease

## Interventions

- **DRUG:** Itolizumab
- **DRUG:** Methylprednisolone

## Key facts

- **NCT ID:** NCT05823675
- **Lead sponsor:** Biotech Pharmaceutical Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-19
- **Primary completion:** 2024-10
- **Final completion:** 2025-02
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2023-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05823675

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05823675, "Safety and Clinical Activity of Itolizumab in aGVHD". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05823675. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*